Partner Content Partner Content Overwhelmed with KOL Data how to navigate through KOL insights & management
Partner Content Partner Content Summarising & Combining Insights Highlight, prioritize & combine your MSL insights
Views & Analysis Improving oncology KOL engagement Combining technology with human insights is a powerful tool in identifying and engaging effectively with oncology experts.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
